GYRE Subsidiary Submits New Drug Application for Lead Candidate F351 (Hydronidone) in China
GYRE is trading near its 52-week low of $6.11 (11% above the low) on elevated volume (2.2× avg).
Summary
Gyre Therapeutics' subsidiary submitted a New Drug Application (NDA) for its lead product candidate, F351 (Hydronidone), in China for chronic hepatitis B-induced liver fibrosis.
Key Events · Product Development and Regulatory · GYRE
-
NDA Submission for Lead Candidate
Gyre Pharmaceuticals Co., Ltd., a majority indirectly owned subsidiary of Gyre Therapeutics, Inc., submitted a New Drug Application (NDA) to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration for F351 (Hydronidone).
-
Targeting Liver Fibrosis in China
The NDA seeks approval for F351 (Hydronidone) for the treatment of chronic hepatitis B (CHB)-induced liver fibrosis, addressing a significant medical need in the Chinese market.
-
Advancing Regulatory Pathway
This submission represents a critical regulatory milestone for the company's lead product candidate, following previously reported successful Phase 3 clinical trial results.
-
Initiation of Review Process
The NDA will undergo initial formatting and completeness verification, with the company anticipating an acceptance number from the CDE before the technical review process begins.
Analysis · GYRE · Life Sciences
This 8-K reports a significant regulatory milestone for Gyre Therapeutics. The submission of a New Drug Application (NDA) for F351 (Hydronidone), the company's lead product candidate, in China for chronic hepatitis B-induced liver fibrosis, marks a critical step towards potential commercialization. This follows the successful Phase 3 results for Hydron previously detailed in the company's 10-K filed on March 13, 2026. While regulatory approval is not guaranteed and the process is subject to CDE review, the NDA submission itself de-risks the development pathway and provides a clear path forward for the drug in a major market.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GYRE was trading at $6.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $610.8M. The 52-week trading range was $6.11 to $11.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.